ALAN EZEKOWITZ

Alan Ezekowitz is a distinguished Venture Partner at Third Rock Ventures, a leading life sciences venture capital firm renowned for its company creation model. In this capacity, Dr. Ezekowitz brings a wealth of experience and strategic insight to the firm's mission of building innovative biotech and healthcare companies from the ground up. His role involves identifying promising scientific breakthroughs, collaborating with founders to develop robust business strategies, and guiding the early-stage development of novel therapeutic platforms.

Dr. Ezekowitz's investment focus at Third Rock Ventures centers on areas of high unmet medical need, particularly in immunology, infectious diseases, and broader therapeutic development. He is instrumental in shaping companies that aim to translate cutting-edge scientific research into impactful medicines for patients. His expertise is invaluable in assessing scientific rigor, navigating complex drug development pathways, and building strong leadership teams within new ventures.

Before joining Third Rock Ventures, Dr. Ezekowitz had a prolific career spanning both academia and industry. He served as Senior Vice President and Franchise Head for Bone, Respiratory, Immunology, and Endocrine at Merck Research Laboratories, where he oversaw significant drug discovery and development programs. His leadership at Merck provided him with deep insights into the challenges and opportunities of bringing new therapies to market on a global scale. Prior to his tenure in the pharmaceutical industry, Dr. Ezekowitz held prominent academic positions. He was a Professor of Pediatrics at Harvard Medical School and served as Chief of Infectious Diseases at Boston Children's Hospital. His academic research focused on innate immunity and infectious diseases, laying a strong scientific foundation for his later work in drug development.

At Third Rock Ventures, Alan Ezekowitz leverages this unique blend of academic research, clinical practice, and industry leadership to foster the creation of companies poised for significant scientific and commercial success. While specific individual investments are often part of a broader Third Rock portfolio, his influence is seen in the strategic direction and scientific rigor of many early-stage biotech companies focused on developing transformative medicines. His contributions are vital in guiding these ventures through critical phases of discovery, preclinical development, and clinical translation, ultimately aiming to deliver novel solutions to patients worldwide.